10 results about "Plasmin" patented technology

The invention belongs to the technical field of earthworm preparations, and discloses an earthworm protein gel candy and a preparation method of the earthworm protein gel candy. 300 parts of apple pectin; 1800 parts of a sorbitol solution; 1000 parts of erythritol is used as a raw material; 4 parts of stevioside; 480 parts of xylitol; 200 g of earthworm protein freeze-dried powder; 20 parts of L-arginine hydrochloride; 300 parts of purified water; 5 parts of citric acid; 20 parts of concentrated fruit juice and natural essence; 5 parts of sodium citrate; and 5 parts of potassium sorbate. According to the local dragon protein gel candy, the L-arginine promotes NO synthesis and accelerates microcirculation improvement; a fruit flavor masking technology is adopted, so that most of unpleasant odors are eliminated, and the gel matrix has long-acting thrombolysis activity and stability; due to beta-cyclodextrin microencapsulation, the gastric solubility of earthworm protein is reduced, the targeted release rate of intestinal tracts is increased, and the activity retention rate of plasmin is increased; the water activity is less than or equal to 0.62, the microbial proliferation is inhibited, and no salmonella / staphylococcus aureus is detected.

The present invention provides a composition, a preparation method and an application for improving male reproductive ability, belonging to the field of bioengineering technology. It is prepared from the following raw materials by weight: 10-30 parts of Bacillus subtilis fibrinolytic enzyme, 5-15 parts of Haematococcus pluvialis, 3-10 parts of walnut kernel extract, 3-10 parts of Cordyceps militaris extract, and 0.3-0.5 parts of rice bran alkanol; the Bacillus subtilis fibrinolytic enzyme is prepared by fermenting the strain Bacillus subtilis QK02, and the strain is preserved in the China Center for Type Culture Collection with the preservation number CCTCC NO: M 203078. The present invention provides a Bacillus subtilis fibrinolytic enzyme composition with the efficacy of improving male reproductive ability, rationally compatible with medicinal and edible ingredients, having a significant synergistic effect, promoting human blood circulation and metabolism, eliminating fatigue, supplementing androgen, and significantly improving human immunity.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The invention discloses a preparation method of a fermented soya bean plasmin composition. The invention relates to a fermented soya bean plasmin composition and a preparation method thereof. The fermented soya bean plasmin composition simultaneously contains fermented soya bean plasmin and fermented soya bean plasmin crude extraction residual solid dry powder. Wherein the fermented soya bean plasmin crude extraction residual solid dry powder is a byproduct for preparing fermented soya bean plasmin, can be used as a bitter taste flavoring agent, a solubilizer or a lipid regulator, and can reduce or avoid repeated addition of corresponding auxiliary components in functional foods or special medical foods. And secondary development and utilization of byproducts for preparing the plasmin of the fermented soya beans are realized, so that the additional value of a final product is improved while the emission of fermentation wastes is reduced.

The invention discloses a sample diluent for plasma sample fluorescent microsphere test strip detection and a preparation method and application thereof. The sample diluent contains a buffer solution, a stabilizer, a surfactant, a preservative, fibrinolytic enzyme and metal ion salt; the buffer solution is a boric acid-borax buffer solution; the stabilizer is any one of casein and bovine serum albumin; the surfactant is Tween 20; the preservative is any one or a combination of two of sodium azide and disodium ethylene diamine tetraacetate; the fibroprotease is earthworm fibrinolytic enzyme; the metal ion salt is sodium chloride. According to the invention, it is creatively found that the detection performance of a plasma sample for fluorescent microsphere test strip detection can be improved by adding fibrinolytic enzyme into a conventional sample diluent, the detection time is shortened, the detection accuracy is improved, and the sample applicability is improved.

The invention relates to a chickpea plasmin supramolecular eutectic crystal and a preparation method and application thereof, the preparation method comprises the following steps: A, fermentation culture: putting chickpeas into a fermentation culture medium, inoculating a Bacillus subtilis natto strain, and fermenting for 48-72 hours under the conditions of 35-40 DEG C and 150-200 rpm; b, crude enzyme extraction: centrifuging the fermentation liquid, adding ammonium sulfate, centrifuging again, taking precipitate, and dissolving the precipitate with a phosphate buffer solution to obtain a crude enzyme solution; c, supramolecular eutectic formation: adding an eutectic ligand into the crude enzyme liquid to perform a co-crystallization reaction to obtain a supramolecular eutectic product; D, post-treatment: performing centrifugal separation and absolute ethyl alcohol washing on the co-crystallization product, and performing vacuum freeze drying under the conditions of-50 to-40 DEG C and 10-30 Pa to obtain the chickpea plasmin supramolecular eutectic. The preparation process can effectively reduce the production cost, and the prepared chickpea plasmin supramolecular co-crystal has the advantages of high enzyme activity, good stability and high purity, and can be effectively applied to drugs or functional foods for treating or preventing thrombotic diseases.

The invention relates a novel isolated recombinant fibrinogen and to a eucaryotic cell producing said novel recombinant fibrinogen, as well as to a fibrin sealant and a fibrin sealant kit comprising the novel isolated recombinant fibrinogen. Furthermore, the present invention relates to a new method for the production of recombinant fibrinogen using eucaryotic cells, and to a new method for identifying novel recombinant fibrinogen variants with reduced sensitivity to proteolytic cleavage by plasmin without losing their suitability as fibrinogen component in a fibrin sealant.

This invention discloses a fibrinolytic enzyme-producing Pseudomonas hygroscopicus originating from mangrove wetlands (… Fictibacillus rigui The strain QMS71 is deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession number CGMCC No. 37018. Under suitable culture conditions, strain QMS71 can produce extracellular enzymes with fibrin-degrading activity. Its fermentation products exhibit significant fibrin degradation activity in vitro and demonstrate thrombolytic and anticoagulant activities in relevant in vitro functional evaluation models. This invention provides a well-identified fibrinolytic enzyme-producing microbial resource and its applications, which can be used for in vitro functional evaluation, model studies, and functional enzymology research related to fibrin degradation.

This invention relates to the field of microbial technology and its application. Xylaria curta (QPZ-01) is deposited at the Guangdong Provincial Microbial Culture Collection Center (GDMCC NO: 64782) on July 10, 2024. The invention also discloses its application in the fermentation of fibrinolytic enzymes. This invention provides an Xylaria curta strain and its application.